Amylyx Pharmaceuticals Inc (AMLX)
5.715
+0.08
(+1.33%)
USD |
NASDAQ |
Nov 04, 16:00
5.715
0.00 (0.00%)
After-Hours: 20:00
Amylyx Pharmaceuticals Debt to Equity Ratio: 0.00 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Sep 2022
--
Maximum
Sep 2022
--
Average
--
Median
Sep 2022
Debt to Equity Ratio Benchmarks
| PTC Therapeutics Inc | -0.2906 |
| NovaBay Pharmaceuticals Inc | -1.128 |
| Palatin Technologies Inc | 0.00 |
| iBio Inc | 0.0461 |
| Theriva Biologics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 332.16M |
| Total Liabilities (Quarterly) | 70.85M |
| Shareholders Equity (Quarterly) | 261.31M |
| Current Ratio | 4.662 |